Fulcrum Therapeutics Inc
NASDAQ:FULC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
FatPipe Inc
NASDAQ:FATN
|
US |
|
MediciNova Inc
NASDAQ:MNOV
|
US |
|
N
|
Nippon Television Holdings Inc
TSE:9404
|
JP |
|
N
|
Next PLC
F:NXG
|
UK |
Fulcrum Therapeutics Inc
Research & Development
Fulcrum Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Research & Development
-$56.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Fulcrum Therapeutics Inc
Glance View
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).
See Also
What is Fulcrum Therapeutics Inc's Research & Development?
Research & Development
-56.1m
USD
Based on the financial report for Dec 31, 2025, Fulcrum Therapeutics Inc's Research & Development amounts to -56.1m USD.
What is Fulcrum Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
1%
Over the last year, the Research & Development growth was 11%. The average annual Research & Development growth rates for Fulcrum Therapeutics Inc have been 10% over the past three years , 1% over the past five years .
